The Therapeutic CD38 Monoclonal Antibody Daratumumab Induces Programmed Cell Death via Fcγ Receptor–Mediated Cross-Linking
Open accessThe DOI matches its Crossref record; 48 of the 51 references it cites were found in a registry or an index.
Abstract
Emerging evidence suggests that FcγR-mediated cross-linking of tumor-bound mAbs may induce signaling in tumor cells that contributes to their therapeutic activity. In this study, we show that daratumumab (DARA), a therapeutic human CD38 mAb with a broad-spectrum killing activity, is able to induce programmed cell death (PCD) of CD38+ multiple myeloma tumor cell lines when cross-linked in vitro by secondary Abs or via an FcγR. By comparing DARA efficacy in a syngeneic in vivo tumor model using FcRγ-chain knockout or NOTAM mice carrying a signaling-inactive FcRγ-chain, we found that the inhibitory FcγRIIb as well as activating FcγRs induce DARA cross-linking–mediated PCD. In conclusion, our in vitro and in vivo data show that FcγR-mediated cross-linking of DARA induces PCD of CD38-expressing multiple myeloma tumor cells, which potentially contributes to the depth of response observed in DARA-treated patients and the drug’s multifaceted mechanisms of action.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Jiang, H., Acharya, C., An, G., Zhong, M., Feng, X., Wang, L., Dasilva, N., Song, Z., Yang, G., Adrian, F., et al. (2016) · Leukemia · doi:10.1038/leu.2015.240 · Cited by 219 · cited 1×
“The homotypic aggregation–related caspase-independent and -dependent PCD was also shown for SAR650984, a chimeric CD38 Ab (40, 41), in the absence of secondary cross-linking.”
BackgroundRetractedKyle, R. A., & Rajkumar, S. V. (2004) · New England Journal of Medicine · doi:10.1056/nejmra041875 · Cited by 1,296
Zamzami, N., Marchetti, P., Castedo, M., Zanin, C., Vayssière, J. L., Petit, P. X., & Kroemer, G. (1995) · The Journal of experimental medicine · doi:10.1084/jem.181.5.1661 · Cited by 1,166
Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma
Lokhorst, H. M., Plesner, T., Laubach, J. P., Nahi, H., Gimsing, P., Hansson, M., Minnema, M. C., Lassen, U., Krejcik, J., Palumbo, A., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1506348 · Cited by 1,117 · cited 1×
“Approval was based on two phase II studies of DARA monotherapy (16 mg/kg) in heavily treated patients (2, 3).”
Methodde Weers, M., Tai, Y.-T., van der Veer, M. S., Bakker, J. M., Vink, T., Jacobs, D. C. H., Oomen, L. A., Peipp, M., Valerius, T., Slootstra, J. W., et al. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1003032 · Cited by 1,037
Self-citationMössner, E., Brünker, P., Moser, S., Püntener, U., Schmidt, C., Herter, S., Grau, R., Gerdes, C., Nopora, A., van Puijenbroek, E., et al. (2010) · Blood · doi:10.1182/blood-2009-06-225979 · Cited by 981
Krejcik, J., Casneuf, T., Nijhof, I. S., Verbist, B., Bald, J., Plesner, T., Syed, K., Liu, K., van de Donk, N. W. C. J., Weiss, B. M., et al. (2016) · Blood · doi:10.1182/blood-2015-12-687749 · Cited by 954
FcR γ chain deletion results in pleiotrophic effector cell defects
Takai, T., Li, M., Sylvestre, D., Clynes, R., & Ravetch, J. V. (1994) · Cell · doi:10.1016/0092-8674(94)90115-5 · Cited by 951
Lonial, S., Weiss, B. M., Usmani, S. Z., Singhal, S., Chari, A., Bahlis, N. J., Belch, A., Krishnan, A., Vescio, R. A., Mateos, M. V., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01120-4 · Cited by 854 · cited 1×
“Approval was based on two phase II studies of DARA monotherapy (16 mg/kg) in heavily treated patients (2, 3).”
MethodApoptosis of Malignant Human B Cells by Ligation of CD20 With Monoclonal Antibodies
Shan, D., Ledbetter, J. A., & Press, O. W. (1998) · Blood · doi:10.1182/blood.v91.5.1644 · Cited by 576
Cited by
Items 101–200 of 314
Translating the anti-myeloma activity of Natural Killer cells into clinical application
Fionda, C., Stabile, H., Molfetta, R., Soriani, A., Bernardini, G., Zingoni, A., Gismondi, A., Paolini, R., Cippitelli, M., & Santoni, A. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.10.005 · Cited by 36
CD38 and Anti-CD38 Monoclonal Antibodies in AL Amyloidosis: Targeting Plasma Cells and beyond
Roccatello, D., Fenoglio, R., Sciascia, S., Naretto, C., Rossi, D., Ferro, M., Barreca, A., Malavasi, F., & Baldovino, S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21114129 · Cited by 36
Isatuximab in the Treatment of Multiple Myeloma: A Review and Comparison With Daratumumab
Shen, F., & Shen, W. (2022) · Technology in Cancer Research & Treatment · doi:10.1177/15330338221106563 · Cited by 36
Fu, W., Bang, S., Huang, H., Kım, K., Li, W., An, G., Lee, J., Cai, Z., Jin, J., Wang, Y., et al. (2023) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2023.02.009 · Cited by 36
Regulation of CD38 on Multiple Myeloma and NK Cells by Monoclonal Antibodies
Wu, H., & Zhao, X. (2022) · International Journal of Biological Sciences · doi:10.7150/ijbs.68148 · Cited by 35
Targeting CD38 in Neoplasms and Non-Cancer Diseases
Szlasa, W., Czarny, J., Sauer, N. J., Rakoczy, K., Szymańska, N., Stecko, J., Kołodziej, M., Kaźmierczak, M., & Barg, E. (2022) · Cancers · doi:10.3390/cancers14174169 · Cited by 35
Xu, X. S., Dimopoulos, M. A., Sonneveld, P., Ho, P. J., Belch, A., Leiba, M., Capra, M., Gomez, D., Medvedova, E., Iida, S., et al. (2018) · Advances in Therapy · doi:10.1007/s12325-018-0815-9 · Cited by 34
Xing, L., Wang, S., Liu, J., Yu, T., Chen, H., Wen, K., Li, Y., Lin, L., Hsieh, P. A., Cho, S., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-1621 · Cited by 34
Treating Multiple Myeloma in the Context of the Bone Marrow Microenvironment
Ho, M., Xiao, A. H., Yi, D., Zanwar, S., & Bianchi, G. (2022) · Current Oncology · doi:10.3390/curroncol29110705 · Cited by 34
Corre, J., Vincent, L., Moreau, P., Hébraud, B., Hulin, C., Béné, M. C., Broijl, A., Caillot, D., Delforge, M., Dejoie, T., et al. (2025) · Blood · doi:10.1182/blood.2024027620 · Cited by 33
Dima, D., Ullah, F., Mazzoni, S. A., Williams, L. S., Faiman, B. M., Kurkowski, A., Chaulagain, C. P., Raza, S., Samaras, C. J., Valent, J. N., et al. (2023) · Cancers · doi:10.3390/cancers15072160 · Cited by 33
Ochoa, M. C., Pérez-Ruiz, E., Minute, L., Oñate, C., Pérez, G., Rodríguez, I., Zabaleta, A., Alignani, D., Fernández-Sendin, M., López, A., et al. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1599636 · Cited by 32
Biological Background of Resistance to Current Standards of Care in Multiple Myeloma
Mogollón, P., Díaz-Tejedor, A., Algarín, E. M., Paíno, T., Garayoa, M., & Ocio, E. M. (2019) · Cells · doi:10.3390/cells8111432 · Cited by 32
Suzuki, K., Dimopoulos, M. A., Takezako, N., Okamoto, S., Shinagawa, A., Matsumoto, M., Kosugi, H., Yoon, S., Huang, S., Qin, X., et al. (2018) · Blood Cancer Journal · doi:10.1038/s41408-018-0071-x · Cited by 32
Monoclonal Antibody Therapies in Multiple Myeloma: A Challenge to Develop Novel Targets
Nishida, H., & Yamada, T. (2019) · Journal of Oncology · doi:10.1155/2019/6084012 · Cited by 32
Voorhees, P. M., Rodriguez, C., Reeves, B., Nathwani, N., Costa, L. J., Lutska, Y., Bobba, P., Hoehn, D., Pei, H., Ukropec, J., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2020003642 · Cited by 31
Yan, X., Clemens, P. L., Puchalski, T. A., Lonial, S., Lokhorst, H. M., Voorhees, P. M., Usmani, S. Z., Richardson, P. G. G., Plesner, T., Liu, K., et al. (2017) · Clinical Pharmacokinetics · doi:10.1007/s40262-017-0598-1 · Cited by 31
CD38: targeted therapy in multiple myeloma and therapeutic potential for solid cancers
Jiao, Y., Yi, M., Xu, L., Chu, Q., Yan, Y., Luo, S., & Wu, K. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1814253 · Cited by 31
Eleutherakis‐Papaiakovou, E., Terpos, E., Kanellias, N., Migkou, M., Gavriatopoulou, M., Ntanasis‐Stathopoulos, I., Fotiou, D., Malandrakis, P., Theodorakakou, F., Spiliopoulou, V., et al. (2023) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2023.2253479 · Cited by 30
Monoclonal Antibodies to Treat Multiple Myeloma: A Dream Come True
D’Agostino, M., Innorcia, S., Boccadoro, M., & Bringhen, S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21218192 · Cited by 29
Kastritis, E., Palladini, G. O., Minnema, M. C., Wechalekar, A. D., Jaccard, A., Lee, H. C., Sanchorawala, V., Mollee, P. N., Lu, J., Schönland, S. O., et al. (2026) · Blood · doi:10.1182/blood.2025032099 · Cited by 28
Pouleau, B., Estoppey, C., Suere, P., Nallet, E., Laurendon, A., Monney, T., Ferreira, D. P., Drake, A. C. B., Carretero-Iglesia, L., Macoin, J., et al. (2023) · Blood · doi:10.1182/blood.2022019451 · Cited by 28
Ocular Complications of Checkpoint Inhibitors and Immunotherapeutic Agents: A Case Series
Parikh, R. A., Chaon, B., & Berkenstock, M. (2020) · Ocular Immunology and Inflammation · doi:10.1080/09273948.2020.1766082 · Cited by 27
Salomon‐Perzyński, A., Walter‐Croneck, A., Usnarska‐Zubkiewicz, L., Dytfeld, D., Zielińska, P., Wojciechowska, M., Hołojda, J., Robak, P. J., Pasternak, A., Knopińska‐Posłuszny, W., et al. (2019) · Advances in Medical Sciences · doi:10.1016/j.advms.2019.05.001 · Cited by 26
SAR442085, a novel anti-CD38 antibody with enhanced antitumor activity against multiple myeloma
Kassem, S., Diallo, B., El-Murr, N., Carrié, N., Tang, A., Fournier, A., Bonnevaux, H., Nicolazzi, C., Cuisinier, M., Reguigne-Arnould, I., et al. (2022) · Blood · doi:10.1182/blood.2021012448 · Cited by 26
Sborov, D. W., Baljević, M., Reeves, B., Laubach, J. P., Efebera, Y. A., Rodriguez, C., Costa, L. J., Chari, A., Silbermann, R. W., Holstein, S. A., et al. (2022) · British Journal of Haematology · doi:10.1111/bjh.18432 · Cited by 26
Mayer, K. A., Budde, K., Halloran, P. F., Doberer, K., Rostaing, L. P. E., Eskandary, F. A., Christamentl, A., Wahrmann, M., Regele, H. M., Schranz, S., et al. (2022) · Trials · doi:10.1186/s13063-022-06198-9 · Cited by 25
Walker, Z. J., VanWyngarden, M. J., Stevens, B. M., Abbott, D., Hammes, A., Langouët-Astrié, C. J., Smith, C. A., Palmer, B. E., Forsberg, P. A., Mark, T. M., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2019000122 · Cited by 25
Rapid Progress in Immunotherapies for Multiple Myeloma: An Updated Comprehensive Review
Nishida, H. (2021) · Cancers · doi:10.3390/cancers13112712 · Cited by 25
Therapeutic tactics for targeting B lymphocytes in autoimmunity and cancer
Wemlinger, S. M., & Cambier, J. C. (2023) · European Journal of Immunology · doi:10.1002/eji.202249947 · Cited by 24
Landgren, O., Chari, A., Cohen, Y. C., Spencer, A. G., Voorhees, P. M., Sandhu, I., Jenner, M. W., Smith, D., Cavo, M., van de Donk, N. W. C. J., et al. (2024) · Blood · doi:10.1182/blood.2024025897 · Cited by 24
Fu, W., Li, W., Hu, J., An, G., Wang, Y., Fu, C., Chen, L., Jin, J., Cen, X., Ge, Z., et al. (2022) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2022.10.007 · Cited by 23
Cytotoxic IgG: Mechanisms, functions, and applications
Wöhner, M., & Nimmerjahn, F. (2025) · Immunity · doi:10.1016/j.immuni.2025.05.008 · Cited by 22
Stocker, N., Gaugler, B., Ricard, L., de Vassoigne, F., Marjanovic, Z., Mohty, M., & Malard, F. (2020) · Cancer Medicine · doi:10.1002/cam4.2827 · Cited by 22
Gambles, M. T., Li, J., Radford, D. C., Sborov, D. W., Shami, P. J., Yang, J., & Kopec̆ek, J. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.08.045 · Cited by 22
Switching to daratumumab SC from IV is safe and preferred by patients with multiple myeloma
Mateos, M., Rigaudeau, S., Basu, S., Špıčka, I., Schots, R., Wróbel, T., Cook, G., Beksaç, M., Gries, K. S., Kudva, A., et al. (2022) · Journal of Oncology Pharmacy Practice · doi:10.1177/10781552221103551 · Cited by 21
Role of daratumumab in the frontline management of multiple myeloma: a narrative review
Yadav, S., Gundeti, S., Bhave, A. A., Deb, U., Dixit, J., & Mishra, K. (2023) · Expert Review of Hematology · doi:10.1080/17474086.2023.2246651 · Cited by 21
Syed, Y. Y. (2019) · Drugs · doi:10.1007/s40265-019-01080-6 · Cited by 21
The multi-faceted potential of CD38 antibody targeting in multiple myeloma
Shallis, R. M., Terry, C. M., & Lim, S. H. (2017) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-017-1990-2 · Cited by 20
The hallmarks of oncogenic signaling: From pathways to resistance in cancer therapy
Tufail, M., Gong, K., Ijaz, B., Patel, H. H., Lui, W., Wang, X., & Li, J. (2026) · Drug Resistance Updates · doi:10.1016/j.drup.2026.101355 · Cited by 20
Targeting CD38 with daratumumab is lethal to Waldenström macroglobulinaemia cells
Paulus, A., Manna, A., Akhtar, S., Paulus, S. M., Sharma, M., Coignet, M. V., Jiang, L., Roy, V., Witzig, T. E., Ansell, S. M., et al. (2018) · British Journal of Haematology · doi:10.1111/bjh.15515 · Cited by 20
Németh, T., Futosi, K., Szabó, M., Aradi, P., Saito, T., Mócsai, A., & Jakus, Z. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00252 · Cited by 20
Jiang, X. Y., Luider, J. M., & Shameli, A. (2019) · Cytometry Part B Clinical Cytometry · doi:10.1002/cyto.b.21837 · Cited by 20
Evolving Role of Daratumumab: From Backbencher to Frontline Agent
Jain, A., & Ramasamy, K. (2020) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2020.03.010 · Cited by 20
Luo, M., Usmani, S. Z., Mateos, M., Nahi, H., Chari, A., Miguel, J. F. S., Touzeau, C., Suzuki, K., Kaiser, M., Carson, R. L., et al. (2020) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1771 · Cited by 20
Kaufman, J. L., Dimopoulos, M. A., White, D. J., Benboubker, L., Cook, G., Leiba, M., Morton, J., Ho, P. J., Kım, K., Takezako, N., et al. (2020) · Blood Cancer Journal · doi:10.1038/s41408-020-00375-2 · Cited by 20
Plesner, T., Dimopoulos, M. A., Oriol, A., Miguel, J. F. S., Bahlis, N. J., Rabin, N. K., Suzuki, K., Yoon, S., Ben‐Yehuda, D., Cook, G., et al. (2021) · British Journal of Haematology · doi:10.1111/bjh.17435 · Cited by 20
Arnall, J. R., Maples, K. T., Harvey, R. D., & Moore, D. C. (2021) · Annals of Pharmacotherapy · doi:10.1177/10600280211058754 · Cited by 20
Fu, W., Bang, S., Huang, H., Kım, K., Li, W., An, G., Lee, J., Cai, Z., Jin, J., Wang, Y., et al. (2024) · Annals of Hematology · doi:10.1007/s00277-024-05958-8 · Cited by 19
Soefje, S. A., Carpenter, C. L., Carlson, K., Awasthi, S., Lin, T. S., Kaila, S., Tarjan, D., Kayal, N., Kirkup, C., Wagner, T. E., et al. (2023) · JCO Oncology Practice · doi:10.1200/op.22.00421 · Cited by 19
Which therapies will move to the front line for multiple myeloma?
Cejalvo, M. J., & de la Rubia, J. (2017) · Expert Review of Hematology · doi:10.1080/17474086.2017.1317589 · Cited by 19
Usmani, S. Z., Khan, I., Chiu, C. W., Foureau, D., Druhan, L. J., Rigby, K., Casneuf, T., & Sasser, A. K. (2018) · Experimental Hematology and Oncology · doi:10.1186/s40164-018-0096-7 · Cited by 19
Hungria, V., Beksaç, M., Weisel, K. C., Nooka, A. K., Masszi, T., Špıčka, I., Munder, M., Mateos, M., Mark, T. M., Qi, M., et al. (2021) · British Journal of Haematology · doi:10.1111/bjh.17321 · Cited by 18
Yimer, H. A., Melear, J. M., Faber, E. A., Bensinger, W., Burke, J. M., Narang, M., Stevens, D. A., Gray, K. S., Lutska, Y., Bobba, P., et al. (2022) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2022.2076847 · Cited by 18
Daratumumab: Therapeutic asset, biological trap!
Deneys, V., Thiry, C., Frelik, A., Debry, C., Martin, B., & Doyen, C. (2018) · Transfusion Clinique et Biologique · doi:10.1016/j.tracli.2017.12.001 · Cited by 18
Crosslinking of CD38 Receptors Triggers Apoptosis of Malignant B Cells
Gambles, M. T., Li, J., Wang, J., Sborov, D. W., Yang, J., & Kopec̆ek, J. (2021) · Molecules · doi:10.3390/molecules26154658 · Cited by 18
Moreau, P., Facon, T. T. F., Usmani, S. Z., Bahlis, N. J., Raje, N. S., Plesner, T., Orlowski, R. Z., Basu, S., Nahi, H., Hulin, C., et al. (2025) · Leukemia · doi:10.1038/s41375-024-02506-1 · Cited by 17
Reprint of “Immunomodulatory effects of CD38-targeting antibodies”
van de Donk, N. W. C. J. (2019) · Immunology Letters · doi:10.1016/j.imlet.2019.02.002 · Cited by 17
Panaampon, J., Kariya, R., & Okada, S. (2021) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-021-03054-8 · Cited by 17
Cohen, Y. C., Oriol, A., Wu, K. L., Lavi, N., Vlummens, P., Jackson, C. C., Garvin, W., Carson, R. L., Crist, W. A., Fu, J., et al. (2020) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2020.08.008 · Cited by 17
Application of CD38 monoclonal antibody in kidney disease
Chen, Z., Xu, Q., & Shou, Z. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1382977 · Cited by 16
Selective targeting of CD38 hydrolase and cyclase activity as an approach to immunostimulation
Benton, T. Z., Mills, C. M., Turner, J. M., Francis, M. J., Solomon, D. J., Burger, P. B., Peterson, Y. K., Dolloff, N. G., Bachmann, A. S., & Woster, P. M. (2021) · RSC Advances · doi:10.1039/d1ra06266b · Cited by 16
Abdallah, A.-O. A., Mahmoudjafari, Z., Ahmed, N., Cui, W., Shune, L. O., McGuirk, J. P., Mohan, M., Mohyuddin, G. R., Afrough, A., Alkharabsheh, O. A., et al. (2023) · European Journal Of Haematology · doi:10.1111/ejh.13942 · Cited by 16
Golay, J. (2017) · Journal of Autoimmunity · doi:10.1016/j.jaut.2017.06.002 · Cited by 16
Monoclonal Antibody: A New Treatment Strategy against Multiple Myeloma
Cho, S., Lin, L., Xing, L., Yu, T., Wen, K., Anderson, K. C., & Tai, Y. (2017) · Antibodies · doi:10.3390/antib6040018 · Cited by 16
Flexibly coupled multiprocessors for image processing
Sunwoo, M. H., & Aggarwal, J. K. (1990) · Journal of Parallel and Distributed Computing · doi:10.1016/0743-7315(90)90021-g · Cited by 16
Spencer, A. G., Moreau, P., Mateos, M., Goldschmidt, H., Suzuki, K., Levin, M., Sonneveld, P., Orlowski, R. Z., Yoon, S., Usmani, S. Z., et al. (2023) · Blood Advances · doi:10.1182/bloodadvances.2023010579 · Cited by 15
Rifkin, R. M., Singer, D., Aguilar, K. M., Baidoo, B., & Maiese, E. M. (2019) · Clinical Therapeutics · doi:10.1016/j.clinthera.2019.03.013 · Cited by 15
Suzuki, K., Wechalekar, A. D., Kım, K., Shimazaki, C., Kim, J. S., Ikezoe, T., Min, C., Zhou, F., Cai, Z., Chen, X., et al. (2023) · Annals of Hematology · doi:10.1007/s00277-023-05090-z · Cited by 15
Jelínek, T., Maisnar, V., Pour, L., Špıčka, I., Minařík, J., Gregora, E., Kessler, P., Sýkora, M., Fraňková, H., Adamová, D., et al. (2017) · Current Medical Research and Opinion · doi:10.1080/03007995.2017.1410121 · Cited by 15
Sanden, S. V., Ito, T., Diels, J., Vogel, M., Belch, A. R., & Oriol, A. (2017) · The Oncologist · doi:10.1634/theoncologist.2017-0103 · Cited by 15
Therapeutic antibodies for multiple myeloma
Ishida, T. (2018) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyy133 · Cited by 14
Xu, X. S., Moreau, P., Usmani, S. Z., Lonial, S., Jakubowiak, A. J., Oriol, A., Krishnan, A. Y., Bladé, J., Luo, M., Sun, Y., et al. (2020) · Advances in Therapy · doi:10.1007/s12325-020-01247-8 · Cited by 14
Practical Considerations for Antibodies in Myeloma
Laubach, J. P., van de Donk, N. W. C. J., Davies, F. E., & Mikhael, J. R. (2018) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_205443 · Cited by 14
Motais, B., Charvátová, S., Walek, Z., Hrdinka, M., Smolarczyk, R., Cichoń, T., Czapla, J., Giebel, S., Šimíček, M., Jelínek, T., et al. (2021) · Cells · doi:10.3390/cells10050967 · Cited by 14
New developments in the treatment of multiple myeloma – clinical utility of daratumumab
McEllistrim, C., Krawczyk, J., & O'Dwyer, M. E. (2017) · Biologics · doi:10.2147/btt.s97633 · Cited by 13
Lu, Y., Zhou, F., Cheng, D., Xie, M., Yan, X., Xue, Y., Yang, Q., Jia, R., Zhong, L., Yang, L., et al. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1240318 · Cited by 13
Why Immunotherapy Fails in Multiple Myeloma
Rodríguez‐Lobato, L. G., Oliver‐Caldés, A., Moreno, D. F., de Larrea, C. F., & Bladé, J. (2020) · Hemato · doi:10.3390/hemato2010001 · Cited by 13
Shrestha, P., Astter, Y., Davis, D. A., Zhou, T., Yuan, C. M., Ramaswami, R., Wang, H., Lurain, K. A., & Yarchoan, R. (2023) · OncoImmunology · doi:10.1080/2162402x.2022.2163784 · Cited by 13
Vočková, P., Svatoň, M., Karolová, J., Pokorna, E., Vokurka, M., & Klener, P. (2020) · Folia Biologica · doi:10.14712/fb2020066010017 · Cited by 13
Liu, W., Yu, J., Sun, K., Song, Q., Li, Y., He, Y., Wang, Y., Xu, G., Wang, C., & Chen, B. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1410457 · Cited by 12
Iida, S., Ishikawa, T., Min, C., Kım, K., Yeh, S. P., Usmani, S. Z., Mateos, M., Nahi, H., Heuck, C. J., Qin, X., et al. (2021) · Annals of Hematology · doi:10.1007/s00277-021-04405-2 · Cited by 12
Yan, X., Xu, X. S., Weisel, K. C., Mateos, M., Sonneveld, P., Dimopoulos, M. A., Usmani, S. Z., Bahlis, N. J., Puchalski, T. A., Ukropec, J., et al. (2020) · Clinical and Translational Science · doi:10.1111/cts.12836 · Cited by 12
Jakubowiak, A. J., Usmani, S. Z., Krishnan, A. Y., Lonial, S., Comenzo, R. L., Wang, J., de Boer, C., Deraedt, W. M., Weiss, B. M., Schecter, J. M., et al. (2021) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2021.05.017 · Cited by 12
Geraldes, C., Neves, M. L., Chacim, S. P., & da Costa, F. L. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2021.817762 · Cited by 12
Terpos, E., Dimopoulos, M. A., Boccadoro, M., Delimpasi, S., Beksaç, M., Katodritou, E., Moreau, P., Pompa, A., Symeonidis, A. S., Bila, J., et al. (2022) · American Journal of Hematology · doi:10.1002/ajh.26480 · Cited by 12
Guzzeloni, V., Veschini, L., Pedica, F., Ferrero, E., & Ferrarini, M. (2022) · Antibodies · doi:10.3390/antib11030046 · Cited by 12
Vermariën-Wang, J., Doeleman, T., van Doorn, R., Mooyaart, A. L., Blokx, W. A. M., & Schrader, A. M. R. (2022) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2022.11.019 · Cited by 11
Richard, S., Jagannath, S., Cho, H. J., Parekh, S. S., Madduri, D., Richter, J. R., & Chari, A. (2020) · Expert Review of Hematology · doi:10.1080/17474086.2021.1858790 · Cited by 11
Fujisaki, T., Ishikawa, T., Takamatsu, H., Suzuki, K., Min, C., Lee, J. H., Wang, J., Carson, R. L., Crist, W. A., Qi, M., et al. (2019) · Annals of Hematology · doi:10.1007/s00277-019-03794-9 · Cited by 11
Daratumumab in multiple myeloma: a guide to its use as monotherapy in the EU
McKeage, K., & Lyseng-Williamson, K. A. (2016) · Drugs & Therapy Perspectives · doi:10.1007/s40267-016-0346-x · Cited by 11
Liu, Y., Yu, S., Chen, Y., Hú, Z., Fan, L., & Liang, G. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1376955 · Cited by 10
Wang, L., Yang, W. C., Wang, Y., Niu, T., Fu, R., Zhong, Y., Qian, W., Ding, K., Sun, K., Liu, H., et al. (2025) · BMC Cancer · doi:10.1186/s12885-025-13925-3 · Cited by 10
Dosne, A., Li, X., Luo, M., Nnane, I. P., Dimopoulos, M. A., Terpos, E., Sonneveld, P., Kampfenkel, T., Carson, R. L., Amin, H., et al. (2022) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15628 · Cited by 10
Takamatsu, H., Iida, S., Shibayama, H., Shibayama, K., Yamazaki, H., & Suzuki, K. (2020) · International Journal of Hematology · doi:10.1007/s12185-020-02825-w · Cited by 10
Cavo, M., Dimopoulos, M. A., Miguel, J. F. S., Mateos, M., Jakubowiak, A. J., Deraedt, W. M., Lam, A., Kampfenkel, T., Qi, M., & He, J. (2020) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2020.02.018 · Cited by 10
Monoclonal antibodies as an addition to current myeloma therapy strategies
Jullien, M., Touzeau, C., & Moreau, P. (2020) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2021.1837627 · Cited by 10
Luo, M., Zhu, P., Nnane, I. P., Xiong, Y., Merlini, G., Comenzo, R. L., Kastritis, E., Wechalekar, A. D., Weiss, B. M., Tran, N., et al. (2021) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1994 · Cited by 10
Daratumumab plus CyBorD for patients with newly diagnosed light chain (AL) amyloidosis
Theodorakakou, F., Dimopoulos, M. A., & Kastritis, E. (2021) · Therapeutic Advances in Hematology · doi:10.1177/20406207211058334 · Cited by 10
Xu, W., Li, D., Sun, Y., Ran, X., Wang, B., Wu, W., Sheng, Z., & Liu, L. (2019) · European Journal Of Haematology · doi:10.1111/ejh.13317 · Cited by 10
Metadata
- Authors
- Overdijk, M. B., Jansen, J. H. M., Nederend, M., Lammerts van Bueren, J. J., Groen, R. W. J., Parren, P. W. H. I., Leusen, J. H. W., & Boross, P.
- Affiliations
- Genmab (Netherlands) (NL)
- University Medical Center Utrecht (NL)
- Genmab , 3584 CM Utrecht,
- University of Southern Denmark (DK)
- Immunotherapy Laboratory, Laboratory for Translational Immunology, University Medical Center , 3584 CX Utrecht,
- ORCID
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2016-08-01
- Volume
- 197
- Issue
- 3
- Pages
- 807-813
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W2443548094
- Cited by
- 297
- References
- 51
- Citations by year
- 2026: 17 · 2025: 22 · 2024: 21 · 2023: 27 · 2022: 35 · 2021: 45 · 2020: 44 · 2019: 34 · 2018: 27 · 2017: 19 · 2016: 4
- FWCI
- 24.29
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- The Journal of Immunology (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
- Utrecht University Repository (Utrecht University) (submittedVersion, other-oa)
- Pure Amsterdam UMC (submittedVersion, other-oa)
- University of Southern Denmark Research Portal (University of Southern Denmark) (submittedVersion)
- Utrecht University Repository (Utrecht University) (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
- Keywords
- daratumumab, anti-CD38 monoclonal antibody, programmed cell death, multiple myeloma, FcRγ chain, FcγRIIB, FcγRIII, antibody-dependent cellular cytotoxicity
- MeSH terms
- Animals, Antibodies, Monoclonal, Antibody-Dependent Cell Cytotoxicity, Antineoplastic Agents, Disease Models, Animal, Humans, Mice, Inbred C57BL, Multiple Myeloma, Tumor Cells, Cultured, Apoptosis, Receptors, IgG, Mice, Knockout, Mice, ADP-ribosyl Cyclase 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.